SEC Filing Summary: Xenomics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Xenomics, Inc. on October 11, 2007, covering events occurring on October 8, 2007. The registrant is incorporated in Florida with principal executive offices in New York, New York. Note: The request metadata referenced "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Xenomics, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance and does not contain financial statements.
Material Changes
The material change reported is the appointment of a principal officer:
- Position: Corporate Controller
- Appointee: Gary Anthony
- Date of Appointment: October 8, 2007
- Prior Experience: Director of Accounting and Compliance at Palatin Technologies, Inc. (Dec 2004–Oct 2007); Consultant to development-stage companies; Controller of INC Research Inc. (Aug 2001–Mar 2003).
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document is limited to the disclosure of the officer appointment under Item 5.02.
Investor Verification Checklist
- Verify the correct registrant name (Xenomics, Inc. vs. Cardiff Oncology, Inc.) in the context of your investment thesis.
- Confirm the background and qualifications of the newly appointed Corporate Controller, Gary Anthony.
- Review subsequent filings for any financial data or strategic updates not included in this governance-focused report.